Business
Ginkgo Bioworks Holdings, Inc.: We must continue to secure and maintain sufficient and stable supplies of laboratory reagents, consumables, equipment, and laboratory services.
Revenue decreased 25.1% to $170.2M, while Net loss narrowed 42.8% to $312.8M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $170.2MWatch
- Profitability — Net loss $312.8MWatch
- Cash generation — Free cash flow −$178.7MNote
- Insiders — 0 buys; 18 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Ginkgo Bioworks Holdings, Inc. reports it. History and quarterly detail are in the app.
- Cell Engineering$132.7M
- Biosecurity$37.4M
Leadership changes
From Ginkgo Bioworks Holdings, Inc.'s own filings, the day they're filed.
- Steven P. Coen · Chief Accounting Officer · appointmenteff. 2023-05-15
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-06-12
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Ginkgo Bioworks Holdings, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.